Heart
01 Jan 2013
STOPAMI
Prevention of myocardial damage is the main goal of all reperfusion therapies in patients with acute myocardial infarction. The relative efficacy of various reperfusion strategies is under intensive investigation. We assessed whether coronary stenting combined with the blockade of platelet glycoprotein IIb/IIIa receptors produces a greater degree of myocardial salvage…
Heart
01 Jan 2013
RAPPORT
The benefit of catheter-based reperfusion for acute myocardial infarction (MI) is limited by a 5 % to 15 % incidence of in-hospital major ischemic events, usually caused by infarct artery reocclusion, and a 20 % to 40 % need for repeat percutaneous or surgical revascularization. Platelets play a key role…
Heart
01 Jan 2013
CADILLAC
As compared with thrombolytic therapy, primary percutaneous transluminal coronary angioplasty (PTCA) in acute myocardial infarction reduces the rates of death, reinfarction, and stroke, but recurrent ischemia, restenosis, and reocclusion of the infarct-related artery remain problematic. When used in combination with PTCA, coronary stenting and platelet glycoprotein IIb/IIIa inhibitors may further…
Heart
01 Jan 2013
EPIC
Platelets are believed to play a part in the ischemic complications of coronary angioplasty, such as abrupt closure of the coronary vessel during or soon after the procedure. Accordingly, we evaluated the effect of a chimeric monoclonal-antibody Fab fragment (c7E3) directed against the platelet glycoprotein IIb/IIIa receptor, in patients undergoing…
Heart
01 Jan 2013
SPEED
Low-dose alteplase with standard-dose abciximab enhances reperfusion 90 minutes after acute myocardial infarction (MI). We combined standard-dose abciximab with low-dose reteplase for acute MI in 2 phases. Two heparin doses were also explored. Phase A patients were randomized 4:1 to receive an abciximab bolus with infusion alone (n = 63)…
Heart
01 Jan 2013
IMPACT-AMI
Platelet activation and aggregation may be key components of thrombolytic failure to restore and maintain perfusion in acute myocardial infarction. We performed a placebo-controlled, dose-ranging trial of integrilin, a potent inhibitor of platelet aggregation, with heparin, aspirin, and accelerated alteplase. Platelet activation and aggregation may be key components of thrombolytic…
Heart
01 Jan 2013
ASSENT-3
Current fibrinolytic therapies fail to achieve optimum reperfusion in many patients. Low-molecular-weight heparins and platelet glycoprotein IIb/IIIa inhibitors have shown the potential to improve pharmacological reperfusion therapy. We did a randomized, open-label trial to compare the efficacy and safety of tenecteplase plus enoxaparin or abciximab, with that of tencteplase plus…
Heart
01 Jan 2013
VIGOUR trials
The VIGOUR group is an international partnership for sharing information, resources, responsibility and credit. VIGOUR (the Virtual Coordinating Center for Global Collaborative Cardiovascular Research) is an international collaboration of investigators from academic institutions in over 40 countries undertaking clinical trials on treatment for acute cardiovascular events, such as myocardial infarction…
Heart
01 Jan 2013
LIPID trial follow-up
Long-term Intervention with Pravastatin in Ischaemic Disease. The trial has been completed and patients are still being followed up to examine the long-term safety and cost-effectiveness of pravastatin. Official Title Conditions Study Type Study Design Further Details LIPID (Long-term Intervention with Pravastatin in Ischaemic Disease) was a large multicentre trial…
